Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mometasone is a synthetic corticosteroid with anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive properties. It is used to treat various inflammatory conditions including skin disorders (topical), allergic rhinitis and nasal polyps (nasal spray), and asthma (inhaled). Mometasone acts by binding to the glucocorticoid receptor in target cells. This leads to changes in gene transcription that suppress the production of pro-inflammatory proteins and mediators such as prostaglandins and leukotrienes. The drug also reduces the activity of immune cells involved in inflammation like mast cells and eosinophils. Mometasone has a high topical-to-systemic activity ratio due to extensive hepatic metabolism and low systemic bioavailability when administered locally[3][5]. It was developed primarily for its potent local effects with minimal systemic side effects. Developed by Organon and manufactured by Merck.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mometasone.